We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
-1.48%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$80M
AUM Growth
-$34M
Cap. Flow
-$32.7M
Cap. Flow %
-40.93%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$30.2M
2
ML
MoneyLion Inc.
ML
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 82.49%
2 Technology 17.51%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
1
Tyra Biosciences
TYRA
$1.91B
$61.1M 76.34%
4,409,991
– –
AEVA
2
Aeva Technologies
AEVA
$1.26B
$14M 17.51%
3,697,039
– –
RLYB icon
3
Rallybio
RLYB
$84.6M
$4.92M 6.15%
257,464
– –
DAWN
4
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-2,491,561
Closed -$30.2M
ML
5
DELISTED
MoneyLion Inc.
ML
– –
-75,581
Closed -$2.54M

Similar funds

CF
Concorde Financial Dallas, Texas $127M AUM 24.97% 1-Year Est. Return
MF
Midwestern Financial Iowa City, Iowa $127M AUM 13.96% 1-Year Est. Return
SAP
Strategic Advisory Partners Greensboro, North Carolina $127M AUM
S
Storgate Dallas, Texas $127M AUM
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
VDC
Van Diest Capital Poly City, Iowa $127M AUM
SIM
Summitas Investment Management Mckinney, Texas $128M AUM
PC
Pelham Capital London, United Kingdom $128M AUM 34.73% 1-Year Est. Return

Canaan Partners XI's Q4 2023 Portfolio in Review

As of Q4 2023, Canaan Partners XI held 5 positions worth $80M, down 30% from $114M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Canaan Partners XI withdrew a net $32.7M in Q4 2023, closing 2 positions. Its most notable exit was Day One Biopharmaceuticals, an estimated $30.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Technology and Financials.

  • Canaan Partners XI fully exited Day One Biopharmaceuticals in Q4 2023, selling an estimated $30.2M.
  • Canaan Partners XI's ten largest holdings make up 100% of its $80M portfolio in Q4 2023.
  • Canaan Partners XI opened 0 new positions and closed 2 in Q4 2023.
  • Canaan Partners XI's portfolio value fell 30% quarter-over-quarter to $80M.

Based on Canaan Partners XI's 13F filing for Q4 2023, filed 1 Feb 2024.